Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News

  News Archive

Dr John Hutchison Joins Autifony Therapeutics as Chief Medical Officer
Friday, September 04, 2015
Dr Hutchison brings a wealth of experience of clinical drug development in both big pharma and the biotech sector.

EU Approval For Tafinlar® and Mekinist®
Friday, September 04, 2015
Novartis have announced that the European Commission has approved the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Novartis, Amgen Partner
Friday, September 04, 2015
The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule.

Adaptimmune Expands Trial of T-cell Therapy for Synovial Sarcoma
Friday, September 04, 2015
The company have announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

Bristol-Myers Squibb and Promedior Enters into Agreement
Thursday, September 03, 2015
Agreement providing exclusive right to acquire Promedior, Inc. and its novel PRM-151 in development for fibrotic diseases.

Eisai Inc. and Purdue Pharma Enter Worldwide Collaboration
Thursday, September 03, 2015
Companies to develop lemborexant for the potential treatment of insomnia and explore other future indications.

AMRI Announces Agreement with Saneca Pharmaceuticals
Thursday, September 03, 2015
Significantly expands AMRI'S portfolio of controlled substances.

Valeant and AstraZeneca to Partner on Brodalumab
Thursday, September 03, 2015
US and EU regulatory submission planned in moderate-to-severe psoriasis in Q4 2015.

Celgene Completes Acquisition of Receptos
Thursday, September 03, 2015
Significantly enhances Celgene's I&I franchise with the addition of Ozanimod, potentially a best-in-class oral agent in Phase III trials for inflammatory bowel disease and multiple sclerosis.

<< 1 2 3 4 5 6 7 >>
Showing Results 1 - 10 of 3807
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!